VBI Vaccines and SciVac Therapeutics To Live Webcast Joint Conference Call For Shareholders to Discuss Proposed Merger
November 04, 2015 08:30 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass. and VANCOUVER, British Columbia, Nov. 4, 2015 (GLOBE NEWSWIRE) -- As previously announced, VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI") and SciVac Therapeutics Inc. (TSX:VAC) (OTCQX:SVACF)...
VBI Vaccines and SciVac Therapeutics To Hold Joint Conference Call For Shareholders to Discuss Proposed Merger
October 30, 2015 08:30 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass. and VANCOUVER, British Columbia, Oct. 30, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI") and SciVac Therapeutics Inc. (TSX:VAC) (OTCQX:SVACF) ("SciVac") will host a...
SciVac Therapeutics Enters into Agreement to Acquire VBI Vaccines
October 26, 2015 08:30 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, MA and VANCOUVER, British Columbia, Oct. 26, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI") and SciVac Therapeutics Inc. (TSX:VAC) and (OTCQX:SVACF) ("SciVac") announced...
VBI Vaccines Announces Development of a Novel Glioblastoma Immunotherapy Candidate
October 08, 2015 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 8, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") today announced that it has applied its eVLP Platform in the development of a novel therapeutic vaccine...
VBI Vaccines to Present at the 15th Annual Biotech in Europe Forum
September 24, 2015 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 24, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") is scheduled to present at the Sachs Associates' 15th Annual Biotech in Europe Forum on Tuesday, September...
VBI Vaccines Promotes Dr. David E. Anderson to Chief Scientific Officer
September 14, 2015 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 14, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") is pleased to announce the promotion of Dr. David E. Anderson, Ph.D., to Chief Scientific Officer. Dr....
VBI Vaccines Awarded NRC-IRAP Funding to Leverage its eVLP Platform in the Development of a Novel RSV Vaccine Candidate
September 08, 2015 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass. and OTTAWA, Sept. 8, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") has been awarded up to $350,000 CAD in grant funding by the National Research Council-Industrial...
VBI Vaccines to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
September 03, 2015 08:04 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 3, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") is scheduled to present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday,...
VBI Vaccines to Provide an Update on its CMV Vaccine Program at the Tenth Annual IMVACS Summit
August 26, 2015 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 26, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines (Nasdaq:VBIV) ("VBI") is scheduled to present at the Tenth Annual Immunotherapy and Vaccine ("IMVACS") Summit on Wednesday, August...
VBI Vaccines Announces Closing of $6.29 Million Private Placement
August 18, 2015 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 18, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines (Nasdaq:VBIV) ("VBI"), a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large...